• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMA releases paper on biomarker use for comment

EMA releases paper on biomarker use for comment

July 14, 2011
CenterWatch Staff

The European Medicines Agency (EMA) has put out for consultation a reflection paper on the use of pharmacogenomic biomarkers as patient selection and treatment stratification tools in drug development, according to PharmaTimes.

A draft of the paper was agreed by the Pharmacogenomics Working Party of the EMA’s Committee for Medicinal Products for Human Use (CPMP) in March and adopted by the CHMP. The deadline for comments is Nov. 25, 2011.

The paper on methodological issues with pharmacogenomic biomarkers in relation to clinical development and patient selection discusses the role these markers can play in predicting which patients are likely to benefit from a particular medicine or which may be susceptible to side effects.

The availability of techniques facilitating the study of the human genome has led to an “exponential increase” in research into genomic biomarkers (GBMs) for disease diagnosis, as markers of either prognosis or response to treatment, the paper said.

It said GBMs should offer “the advantage of improved specificity and reduction of heterogeneity that is an integral part of phenotypic population grouping.”

This characteristic is seen as highly attractive in drug development, given the potential for GBMs to reduce attrition and development costs through improved understanding of mechanisms of action, better awareness of potential adverse events and use of novel development strategies in pre-clinical and clinical trials.

GBMs may have a wide range of applications in clinical drug development, the paper said, including patient selection; prognoses; stratification of patient groups or treatment strategies; early evaluation of treatment effects, including adverse reactions; pre-defined sub-group analyses; and enabling novel trial designs that “might not be possible otherwise due to heterogeneity of clinical characteristics.”

GBMs could also play a valuable role in risk management strategies, including risk minimization, by prior identification of patients susceptible to severe adverse effects, the paper said.


Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing